A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC

NCT06844474 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC

Interventions

DRUG: SHR-1826；Adebrelimab；SHR-8068；Bevacizumab

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.